IDH2 and glioblastoma: Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) are associated with improved survival rates among patients with glioblastoma and are positive prognostic predictors of overall survival (83, 84).